EVH — Evolent Health, Inc.

Evolent Health (EVH) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $469 million, exceeding the midpoint of guidance.
• Adjusted EBITDA: $37.8 million, also above guidance expectations.
• 2025 Baseline Revenue: $1.77 billion (after adjusting for divestiture).
• 2025 Adjusted EBITDA: Approximately $141 million.
• Medical Expense Ratio (MER) for 2025: 89%, excluding Evolent Care Partners (ECP), showing a 700 basis point improvement from 2024.
• Net Debt: $782 million, below the expected range of $805 million to $840 million.

2. Strategic Updates and Business Highlights

• Evolent is experiencing strong customer retention and growth, with a forecasted revenue growth of approximately 30% for 2026, targeting $2.5 billion in revenue.
• The oncology segment is expected to grow significantly, contributing 65% of total revenue in 2026, up from 36% in 2025.
• Approximately 90% of Performance Suite revenue has been transitioned to a new enhanced model, which includes protective terms and downside risk management.
• Successful contract renegotiations have led to a target margin of 7-10% for new contracts, with potential for higher margins based on performance.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: $2.4 billion to $2.6 billion, driven by new Performance Suite launches.
• Adjusted EBITDA Guidance for 2026: $110 million to $140 million, with expectations for a ramp-up in the second half of the year.
• Anticipated MER for 2026 is approximately 93%, reflecting the impact of new contracts and reserving methodologies.
• The company is targeting a run rate adjusted EBITDA of over $150 million by Q4 2026.

4. Bad News, Challenges, or Points of Concern

• Exchange Membership Declines: A significant headwind from the "One Big Beautiful Bill" has led to an expected $40 million reduction in contribution from exchange membership disenrollment and customer plan closures.
• Initial Contract Reserves: New contracts are being conservatively reserved, leading to a temporary headwind in EBITDA due to higher-than-expected membership volumes and conservative reserving practices.
• Operational Challenges: The company is navigating a contracting membership environment, which presents near-term headwinds despite strong demand for services.

5. Notable Q&A Insights

• Conservative Reserving Approach: The conservative approach to reserving for new contracts is driven by the need to account for initial uncertainties and the ramp-up of new data flows.
• Oncology Cost Trends: The oncology cost trends are expected to remain stable, with a focus on managing therapeutic costs and improving clinical decision-making.
• Pipeline Opportunities: The pipeline remains balanced between Performance Suite and Tech & Services, with significant opportunities expected to contribute to growth in future years.
• Focus on Clarity and Communication: Mario Ramos emphasized the importance of transparency in financial disclosures and ongoing efforts to improve communication with investors.

Overall, Evolent Health is positioned for growth in 2026, particularly in the oncology segment, while facing challenges related to exchange membership and the need for conservative financial management in light of new contracts.